|
BDP1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.95079996601066E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.41700000014333E-08 |
| Normal-vs-Stage2 |
1.174680E-04 |
| Normal-vs-Stage3 |
8.43240000047984E-08 |
| Normal-vs-Stage4 |
1.33999999996082E-06 |
| Stage1-vs-Stage2 |
9.624200E-01 |
| Stage1-vs-Stage3 |
3.112400E-01 |
| Stage1-vs-Stage4 |
4.261600E-01 |
| Stage2-vs-Stage3 |
5.483800E-01 |
| Stage2-vs-Stage4 |
5.818400E-01 |
| Stage3-vs-Stage4 |
9.925600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.11330000166043E-08 |
| Normal-vs-AfricanAmerican |
2.556900E-03 |
| Normal-vs-Asian |
1.9749599999952E-05 |
| Caucasian-vs-AfricanAmerican |
5.847400E-01 |
| Caucasian-vs-Asian |
9.455400E-01 |
| AfricanAmerican-vs-Asian |
5.660200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.70840000321715E-09 |
| Normal-vs-Female |
2.35170000140172E-08 |
| Male-vs-Female |
3.497400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.05500000002756E-06 |
| Normal-vs-Age(41-60Yrs) |
1.11419999893059E-08 |
| Normal-vs-Age(61-80Yrs) |
9.4806000050518E-08 |
| Normal-vs-Age(81-100Yrs) |
8.160400E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.164810E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.234400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.414000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.837400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.341000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.838600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.176560E-01 |
| Classical-VS-Follicular |
1.671590E-01 |
| Classical-VS-Other |
4.116000E-01 |
| Classical-VS-Normal |
1.72799999975659E-07 |
| Tall-VS-Follicular |
5.984400E-01 |
| Tall-VS-Other |
9.886800E-01 |
| Tall-VS-Normal |
1.62696000000073E-05 |
| Follicular-VS-Other |
7.675200E-01 |
| Follicular-VS-Normal |
1.44290000003711E-06 |
| Other-VS-Normal |
1.068480E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.14849996180055E-09 |
| Normal-vs-N1 |
3.410900E-04 |
| N0-vs-N1 |
1.784030E-01 |
|
|
